Premium
Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?
Author(s) -
Zackova Daniela,
Klamova Hana,
Dusek Ladislav,
Muzik Jan,
Polakova Katerina Machova,
Moravcova Jana,
Jurcek Tomas,
Dvorakova Dana,
Racil Zdenek,
Pospisil Zdenek,
Oltova Alexandra,
Michalova Kyra,
Brezinova Jana,
Razga Filip,
Doubek Michael,
Cetkovsky Petr,
Trneny Marek,
Mayer Jiri
Publication year - 2011
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21942
Subject(s) - medicine , discontinuation , imatinib , myeloid leukemia , clinical trial , imatinib mesylate , population , cumulative incidence , oncology , transplantation , environmental health